膦甲酸钠治疗重度黄疸型乙型肝炎的研究  

Effects of foscarnet sodium on severe icteric hepatitis B

作　　者：杨琼慧[1] 周元华[1] 江鸣[1] 张绪清[2] 

机构地区：[1]解放军第8医院传染科,西藏日喀则857000 [2]第三军医大学,重庆400038

出　　处：《西南国防医药》2004年第2期134-135,共2页Medical Journal of National Defending Forces in Southwest China

摘　　要：目的 :探讨膦甲酸钠对重度黄疸型乙型肝炎的抗病毒作用。方法 :用膦甲酸钠治疗 11例轻中度慢性乙型肝炎和2 0例重度黄疸型乙型肝炎 ,并选择同期的 11例轻中度慢性乙型肝炎和 2 0例重度黄疸型乙型肝炎不进行抗病毒治疗作对照。结果 :治疗结束时 ,膦甲酸钠治疗组HBeAg和HBVDNA阴转率分别为 4 2 1%和 6 1 3% ,显著高于对照组 (5 3%和12 9% ) ;重度黄疸型乙型肝炎患者血清HBeAg、HBVDNA阴转率 (75 0 %和 80 0 % )均显著高于轻中度慢性乙型肝炎患者 (18 2 3%和 2 7 3% ) ;治疗结束后 3个月膦甲酸钠治疗组HBeAg和HBVDNA阴转率分别为 2 9 4 %和 4 0 7%。结论Objective:To explore the antiviral effects of foscarnet sodium on severe icteric hepatitis B.Methods:Eleven patients with slight or moderate chronic hepatitis B and 20 patients with severe icteric hepatitis B were all treated by foscasrnet sodium.Meanwhile,another 11 patients with slight or moderate chronic hepatitis B and 20 patients with severe icteric hepatitis B in control group did not receive antiviral treatment.Results:At the end of treatment,the negative conversion rates of HBeAg and HBV DNA in treatment group were 42.1% and 61.3%,respectively,which were significantly higher than that in control group(HBeAg 5.3%,HBV DNA 12.9%).Within the treatment group,the negative conversion rates of HBeAg and HBV DNA in patients with severe icteric hepatitis B were 75% and 80.6%,respectively,which were remarkably higher than that in patients with slight or moderate chronic hepatitis B(HBeAg 18.23%,HBV DNA 27.35).Three months after treatment,the negative conversion rates in treatment group were 29.4% and 40.79%,respectively.Conclusion:Foscarnet sodium is effective in the antiviral treatment of severe icteric hepatitis B.

关 键 词：抗病毒治疗 膦甲酸钠 重度黄疸型乙型肝炎 天门冬氨酸钾镁 药物治疗 

分 类 号：R512.62[医药卫生—内科学] R978.7[医药卫生—临床医学]